Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "human-trial"

39 News Found

Asahi Kasei pushes into human trials with new autoimmune drug candidate
Clinical Trials | April 22, 2026

Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp


GlycoNex wins Japan nod to launch first human trial of lead program in gastrointestinal cancers
Clinical Trials | April 16, 2026

GlycoNex wins Japan nod to launch first human trial of lead program in gastrointestinal cancers

The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy


Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
Clinical Trials | March 14, 2026

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans


Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
News | February 24, 2026

Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy

The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers


Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy
News | February 04, 2026

Onchilles Pharma gets FDA green light for first-in-human trials of breakthrough cancer therapy

N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway


Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA
Clinical Trials | January 29, 2026

Insilico Medicine’s AI-designed Parkinson’s drug cleared for human trials by FDA

The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies


Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
News | January 21, 2026

Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026